You are now leaving Mitsubishi Tanabe Pharma Canada and visiting a third-party website.

If you are interested in exploring careers at MTP-CA, please email
contact@mt-pharma-canada.com.

Media Center

Background Image

Press Releases

  • Mitsubishi Tanabe Pharma Canada Announces That Manitoba has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, June 30, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Alberta

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent with Pan-Canadian Pharmaceutical Alliance for RADICAVA® (edaravone)

    TORONTO, April 22, 2020 - Mitsubishi...

    Read More
  • Update on Canadian Product Availability

    Mitsubishi Tanabe Pharma Canada (MTP-CA)...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Saskatchewan has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, June 30, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Ontario

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • MTP-CA’s Response to COVID-19

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of RADICAVA™ (Edaravone) to Treat ALS

    TORONTO, October 4, 2018 -- Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in New Brunswick

    TORONTO, June 18, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Quebec

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Availability of RADICAVA® (edaravone) for Amyotrophic Lateral Sclerosis

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • New Country Manager Brings Significant Business Leadership and Healthcare Expertise to Mitsubishi Tanabe Pharma Canada, Inc.

    TORONTO, September 28, 2018 – Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Manitoba has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, June 30, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Saskatchewan has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, June 30, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in New Brunswick

    TORONTO, June 18, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Alberta

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Ontario

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Quebec

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent with Pan-Canadian Pharmaceutical Alliance for RADICAVA® (edaravone)

    TORONTO, April 22, 2020 - Mitsubishi...

    Read More
  • MTP-CA’s Response to COVID-19

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Availability of RADICAVA® (edaravone) for Amyotrophic Lateral Sclerosis

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Update on Canadian Product Availability

    Mitsubishi Tanabe Pharma Canada (MTP-CA)...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of RADICAVA™ (Edaravone) to Treat ALS

    TORONTO, October 4, 2018 -- Mitsubishi...

    Read More
  • New Country Manager Brings Significant Business Leadership and Healthcare Expertise to Mitsubishi Tanabe Pharma Canada, Inc.

    TORONTO, September 28, 2018 – Mitsubishi...

    Read More